SYK

Stryker got FDA clearance for its Sonopet 3 ultrasonic platform, built from surgeon input. The move follows a recent 11.63% one‑month share rise but a 7.02% drop over three months.

Stryker’s stock has risen 22.3% over three years but fallen in the last year, raising questions about its current $307.08 price versus cash generation. New products, partnerships and legal issues are all factors in its cash‑flow outlook.

The headline compares PAHC and SYK to determine which is the better value stock right now.

Stryker’s Sonopet 3 received FDA clearance, aiming to improve surgical accuracy and efficiency. A full commercial launch is expected later this fall.

The Zacks analyst blog highlights Abbott, Johnson & Johnson, Stryker, Waste Management and Republic Services as long‑term demand opportunities beyond AI in 2027.

Diamond Hill Capital, a First Eagle Investment Management company, issued its Q3 2026 investor letter for its “Large Cap Strategy”. The letter can be downloaded here. The Strategy returned 3.18% (net of fees) in the quarter, outperforming the 2.61% return of the Russell 1000 Value Index.

Stryker invested $400 million in CMR Surgical, entering soft‑tissue robotics with Versius technology to broaden its surgical portfolio.